Cresemba® and Zevtera®-related revenues rise by 24% to CHF 90.5 million
Total revenue grows significantly by 36% to CHF 104.0 million
Operating profit surges by 160% to CHF 24.0 million
Operating cash flow increases by 29% to CHF 23.1 million
Full-year 2025 guidance: on track and updated to reflect recent in-licensing of a novel oral phase 3-ready antibiotic
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.